Aldeyra Therapeutics rises as eye treatment meets late-stage study goals
15/06/2023 12:23
** Shares of drug developer Aldeyra Therapeutics Inc
ALDX.O rise 11.7% to $11.70 before the bell
** Co says its experimental drug, reproxalap, to treat an
inflammatory eye disease met the main goal of reducing itching
in a late-stage study
** The drug also helped reduce redness and tearing caused
due to the disease when compared to placebo- co
** As of last close, stock had gained 50.22% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora
U.S. STOCKS ON THE MOVE-Qualcomm, Canadian Solar, Draftkings
Aldeyra tumbles to record low after FDA declines to approve experimental dry eye drug
Aldeyra plunges after FDA declines to approve experimental dry eye drug